Utah Medical Products, Inc. (UTMD) wird mit einem nachlaufenden KGV von gehandelt 18.8. Die nachlaufende Gewinnrendite beträgt 5.32%. Die Graham-Zahl beträgt $52.57.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 66/100 mit 4/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | 22.5 | 8.83 | 3.94 | 6.94 | 1.44% |
| 2017 | 35.6 | -1.23 | 3.87 | 7.31 | 0.98% |
| 2018 | 16.7 | 0.14 | 3.48 | 7.38 | 1.30% |
| 2019 | 27.3 | -1.34 | 3.97 | 8.56 | 1.02% |
| 2020 | 28.6 | -1.12 | 3.00 | 7.31 | 1.33% |
| 2021 | 24.7 | 0.66 | 3.40 | 7.43 | 3.14% |
| 2022 | 22.2 | 1.87 | 3.20 | 6.99 | 0.87% |
| 2023 | 18.4 | 20.85 | 2.39 | 6.10 | 1.40% |
| 2024 | 15.5 | -1.16 | 1.83 | 5.26 | 1.98% |
| 2025 | 16.4 | -1.18 | 1.55 | 4.81 | 2.15% |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $3.22 | $39.3M | $12.13M | 30.9% |
| 2017 | $2.28 | $41.41M | $8.51M | 20.5% |
| 2018 | $4.95 | $42M | $18.55M | 44.2% |
| 2019 | $3.94 | $46.9M | $14.73M | 31.4% |
| 2020 | $2.94 | $42.18M | $10.8M | 25.6% |
| 2021 | $4.04 | $49.05M | $14.79M | 30.1% |
| 2022 | $4.52 | $52.28M | $16.47M | 31.5% |
| 2023 | $4.57 | $50.22M | $16.64M | 33.1% |
| 2024 | $3.96 | $40.9M | $13.87M | 33.9% |
| 2025 | $3.48 | $38.52M | $11.29M | 29.3% |
